|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
4.49(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
19,582 |
159,721 |
159,721 |
409,721 |
Total Sell Value |
$1,173,232 |
$10,834,513 |
$10,834,513 |
$25,314,056 |
Total People Sold |
1 |
3 |
3 |
3 |
Total Sell Transactions |
1 |
12 |
12 |
22 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-05 |
4 |
OE |
$12.57 |
$358,245 |
D/D |
28,500 |
216,219 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-04 |
4 |
AS |
$125.02 |
$187,530 |
D/D |
(1,500) |
187,719 |
|
-41% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-08-04 |
4 |
OE |
$12.57 |
$18,855 |
D/D |
1,500 |
189,219 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2021-07-19 |
4 |
AS |
$125.67 |
$1,264,348 |
I/I |
(10,000) |
148,831 |
|
-36% |
|
Novak Rodger |
President |
|
2021-06-30 |
4 |
AS |
$165.00 |
$4,125,000 |
D/D |
(25,000) |
573,007 |
|
-44% |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-29 |
4 |
AS |
$145.92 |
$7,106,341 |
D/D |
(47,536) |
0 |
|
-38% |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
47,536 |
47,536 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-28 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,285,027) |
0 |
|
-36% |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
248,625 |
6,018 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-28 |
4 |
AS |
$150.65 |
$1,524,799 |
I/I |
(10,000) |
158,831 |
|
-36% |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-28 |
4 |
AS |
$150.65 |
$3,106,783 |
D/D |
(20,375) |
0 |
|
-36% |
|
Novak Rodger |
President |
|
2021-06-28 |
4 |
AS |
$156.55 |
$3,913,750 |
D/D |
(25,000) |
598,007 |
|
-36% |
|
Novak Rodger |
President |
|
2021-06-21 |
4 |
AS |
$125.58 |
$3,215,458 |
D/D |
(25,000) |
623,007 |
|
-28% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-06-15 |
4 |
AS |
$125.39 |
$3,792,804 |
D/D |
(30,000) |
187,719 |
|
-21% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-06-15 |
4 |
OE |
$12.57 |
$377,100 |
D/D |
30,000 |
217,719 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2021-06-11 |
4 |
AS |
$125.62 |
$1,266,118 |
D/D |
(10,000) |
20,375 |
|
-21% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2021-06-01 |
4 |
D |
$115.80 |
$90,208 |
D/D |
(779) |
187,719 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-03-23 |
4 |
AS |
$126.97 |
$12,805,240 |
D/D |
(100,000) |
1,050 |
|
-3% |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-03-23 |
4 |
OE |
$14.43 |
$3,170,000 |
D/D |
88,000 |
101,050 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2021-03-22 |
4 |
AS |
$129.36 |
$4,020,667 |
D/D |
(30,374) |
30,375 |
|
-9% |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-03-10 |
4 |
D |
$124.15 |
$265,805 |
D/D |
(2,141) |
13,050 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,583 |
15,191 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-03-10 |
4 |
D |
$124.15 |
$167,975 |
D/D |
(1,353) |
23,911 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,833 |
25,264 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2021-03-10 |
4 |
D |
$124.15 |
$265,805 |
D/D |
(2,141) |
38,304 |
|
- |
|
485 Records found
|
|
Page 5 of 20 |
|
|